TCT-343 Paclitaxel Drug Eluting Balloon Versus Standard Angioplasty To Reduce Restenosis In Diabetic Patients With In Stent Restenosis Of The Superficial Femoral And Proximal Popliteal Artery  by Liistro, Francesco et al.
TCT-341
Impact of Chronic Statin Therapy on Development of Glucose Intolerance
and New-onset Diabetes Mellitus in Asian Population
Sang-Ho Park1, Seung-Woon Rha2, Ung Jun1, Se-Whan Lee1, Won-Yong Shin1,
Seung Jin Lee1, Dong-Kyu Jin1, Byoung Geol Choi2, Se Yeon Choi2, Sung Il Im2,
Sun Won Kim2, Jin Oh Na2, Seong Woo Han2, Cheol Ung Choi2, Hong Euy Lim2,
Jin Won Kim2, Eung Ju Kim2, Chang Gyu Park2, Hong Seog Seo2, Dong Joo Oh2
1Cardiology Department, Soonchunhyang university cheonan hospital, Cheonan,
Korea, Republic of, 2Cardiovascular Center, Korea University Guro Hospital,
Seoul, Korea, Republic of
Background: There have been several reports that statin therapy is associated with a
slightly higher incidence of new-onset diabetes mellitus(DM) or impaired glucose
intolerance(IGT). It is still controversial whether the chronic statin therapy is a risk factor
of IGT and new onset DM, in Asian population.
Methods: We investigated the 13,561 patients(pts) that was HbA1c level 6.0% and
fasting glucose level124 mg/dL(statin therapy group4016 and control group9545).
To adjust potential confounders including age, gender, hypertension, hyperlipidemia,
chronic kidney disease, hyper/hypo-thyroidism, lipid profile, beta-blocker, diuretics, a
propensity score matched analysis was performed using the logistic regression model. The
primary end-point was the cumulative incidence of new-onset DM, IGT, and impaired
fasting glucose(IFG). Also, Multivariable Cox-regression analysis adjusted aforemen-
tioned variables was performed to determine the impact of statin therapy on the incidence
of new-onset DM, IGT, and IFG.
Results: Mean follow-up duration was 534604 days in all group, and 608607 days
in propensity score matching group. Baseline characteristics was similar between the two
groups except hyperlipidemia (11.1% vs. 3.5%, p0.001). In Kaplan-Meyer curve, there
was no difference between the two groups (p0.501, figure A). Also, in cox-regression
analysis performed in all pts, statin therapy was not associated with the increased
incidence of primary end-point(figure B).
Conclusions: In our study, there was no clear association with statin therapy and IGT and
new-onset DM in a series of cardiovascular pts in Asian population.
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Background: Introduction Few data is available on the comparison between diabetic and
non-diabetic patients after percutaneous coronary intervention (PCI) with drug eluting
stents for unprotected left main coronary artery disease. Hypothesis We assessed the
hypothesis that diabetes mellitus is a predictor of worse clinical outcome after PCI with
drug eluting stents for unprotected left main disease.
Methods: This is a multicenter registry enrolling consecutive patients undergoing PCI
with paclitaxel or everolimus-eluting stents for unprotected left main disease. Death,
cardiac death, myocardial infarction (MI), clinically-driven-target lesion revascularization
(TLR), target vessel revascularization (TVR), stroke, definite/probable stent thrombosis
were assessed at 2-year follow-up. A multiple cox regression analysis was performed.
Hazard ratios (HR) with 95% confidence interval (CI) were calculated.
Results: A total of 331 patients, median age 71 yrs-old, (25th-75th percentile 62-78), 87
(26.3%) diabetics, 172 undergoing paclitaxel eluting stent and 159 undergoing everolimus
eluting stent implantation, were enrolled. At 2-year follow-up diabetics, as compared to
non-diabetic patients, presented a higher incidence of death (14.9% vs 4.5%, p0.001),
cardiac death (9.2% vs 2.9%, p0.015), stroke (5.7% vs 0.8%, p0.015), definite/probable
stent thrombosis (3.4% vs 0%, p0.018), the composite of death/MI/stroke, (21.8% vs 9.8%,
p0.004), the composite of death/MI/TLR (22.9% vs 13.1%, p0.03), and the composite of
death/MI/TLR/stroke (25.3% vs 13.5%). No significant differences between diabetics and
non-diabetic patients were found with respect to MI (10.3% vs 6.1%, p0.19), TLR (6.9% vs
4.9%, p0.48) or TVR (16.1% vs 9.4%, p0.09). At multiple cox regression analysis,
diabetes status was a significant predictor of death/MI/stroke (HR 2.39, 95% CI 1.30-4.37,
p0.005), of death/MI/TLR (HR 1.97, 95% CI 1.12-3.46, p0.018) and of death/MI/TLR/
stroke (HR 2.08, 95% CI 1.21-3.58, p0.008).
Conclusions: In patients undergoing PCI with drug eluting stents for unprotected left
main coronary artery disease, diabetes status is associated with a significantly worse
prognosis at 2-year follow-up.
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Background: Plain Old Balloon Angioplasty (POBA) for In-Stent Restenosis (ISR) in
the superficial femoral artery (SFA) and proximal popliteal artery (PA) has a recurrent
stenosis rate of up to 70% within 12 months. Aim of the study was to test the ability to
reduce this high recurrency rate with a Paclitaxel Eluting Balloon (PEB).
Methods: Since January 2010, 44 consecutive patients with symptomatic in-stent restenosis
of the SFA or proximal PA were treated with PEB (Admiral In.Pact, Medtronic, Minnesota,
USA). The occurrence of re-restenosis and repeat intervention at 1-year follow up was
compared to those of 42 consecutive patients treated with POBA from January 2008 to
December 2009.
Results: No significant difference in terms of clinical, angiographic and procedural charac-
teristics were observed among the two study groups. Respectively: Age 7411 in PEB vs
767 in POBA, P0.1; insuline therapy 23/44(50%) vs 21/42(48%), p0.9; Rutherford
Class4 33/44(75%) vs 28/42(67%), p0.8; serum creatinine 1.091.5mg/dL vs
1.021.5mg/dL, p0.9; occlusive ISR 23/44(52%) vs 28/42(66%), p0.1; restenosis length
13186mm vs 13885mm, p0.4. Procedural success, defined as a residual stenosis 30%
in the restenotic segment (stent	5mm of proximal and distal edges), was obtained in all treated
lesions and no adverse clinical events occurred during hospitalization in both groups. At
one-year follow-up, 6 patients died (3 in PEB and 3 in POBA), one patient in POBA group
underwent major amputation. Restenosis, assessed by angiography or ultrasound, occurred in
8/41(19%) PEB vs 28/39(72%) POBA, p0.05. Repeat angioplasty for symptomatic in stent
re-restenosis occurred in 6/44(13%) PEB vs 13/42(31%) POBA, p0.05.
Conclusions: Repeat balloon angioplasty for ISR in the SFA and proximal PA artery
using PEB showed a significant reduction in re-restenosis and repeat angioplasty
compared to POBA at 1-year follow-up.
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Background: Diabetic patients (DP) show more complex coronary artery disease than
non-diabetic patients (N-DP) and diabetes mellitus (DM) predicts adverse outcome after
MI. We sought to investigate the interaction of reperfusion and DM on mortality after
STEMI treated with primary PCI.
Methods: A multicenter registry of consecutive patients treated with primary PCI in 3
centers. Vital status was obtained through municipality records. Reperfusion was scored
by TIMI flow. Cox regression was used to analyze effect modification of the correlation
between sub-optimal reperfusion (TIMI3) and mortality by DM.
Results: In total, 386 DP and 3063 N-DP were treated with primary PCI. DP were older
(66.7 vs. 62.8 years in N-DP, p0.001), less often male (68.4% vs. 75.9% in N-DP,
p0.001), more frequently suffered a previous MI (14.3% in DP vs. 10.3% N-DP,
p0.018) and renal insufficiency (12.5% vs. 2.6% in N-DP, p0.001). Moreover, DP
showed more multi-vessel disease (31.3% vs. 20.3% in N-DP, p0.001). TIMI flow
before and after PCI was similar. Mortality was higher in DP (30 day: 9.1% vs. 3.8% in
N-DP, p0.001, 1 year: 14.5% in DP vs. 6.1% in N-DP, p0.001). Furthermore, DP
patients showed substantially worse 1 year mortality after sub-optimal reperfusion
compared to N-DP (figure), an interaction which was confirmed by cox regression
(interaction HR 2.36, 95% CI 1.11-5.03 after correction for confounders).
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